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Aim: To evaluate the differential effects of fractionated vs. high-dose radiotherapy on plant
growth.
Background: Interest in hypofractionated radiotherapy has increased substantially in recent
years as tumours (especially of the lung, prostate, and liver) can be irradiated with ever
greater accuracy due to technological improvements. The effects of low-dose ionizing radi-
ation  on plant growth have been studied extensively, yet few studies have investigated the
effect of high-dose, hypofractionated radiotherapy on plant growth development.
Materials and methods: A total of 150 plants from the genus Capsicum annuum were random-
ized to receive fractionated radiotherapy (5 doses of 10 Gy each), single high-dose (SHD)
radiotherapy (single 50 Gy dose), or no radiotherapy (control group). Irradiation was deliv-
ered via linear accelerator and all samples were followed daily for 26 days to assess and
compare daily growth.
Results: On day 26, plants in the control, fractionated, and SHD groups had grown to a mean
height of 7.55 cm, 4.32 cm, and 2.94 cm, respectively. These differences in overall growth
were highly signiﬁcant (P = 0.005). The SHD group showed the least amount of growth.
Conclusions: SHD effectively stunts plant growth and development. Despite the evident dif-ferences between plant and animal cells, ionizing radiation is believed to work in a similar
manner in all biological cells. These ﬁndings highlight the need to continue investigating
the  use of hypofractionated schemes in humans to improve cancer treatment outcomes.©  2013 Greater Poland C
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1.  Background
Interest in hypofractionated radiotherapy has increased sub-
stantially in recent years, particularly for certain tumour
localizations (lung, prostate, liver, among others).1 Highly
sophisticated technological developments, such as inten-
sity modulated radiotherapy (IMRT) and stereotactic body
radiotherapy (SBRT) have given clinicians the ability to
deliver increasingly precise doses that conform closely to
the target while minimizing the dose to surrounding healthy
tissue.2,3
The precision of these new technologies permits the use of
higher doses delivered in fewer fractions, an approach known
as hypofractionation, because doses are higher and fewer
compared to normofractionated treatment regimens. These
hypofractionated schemes offer the potential for better local
control and improved outcomes, with less cost and a lower
burden on the patient and a reduced demand on radiothe-
rapy services. However, there is a trade-off: hypofractionation
has a higher risk of adverse effects due to the potential for
irreversible damage to healthy tissue.
Meristematic plant cells, like human cancer cells, undergo
a rapid cell division.4 Meristematic cells are the drivers of
plant growth and when these cells are stressed—by bacte-
rial or viral invasion, or by lack of water or nutrients, growth
will be slowed or even halted. Human cancer cells and mer-
istematic plant cells (particularly in immature plants that
have not yet reached full size) both share a common char-
acteristic: rapid growth. This shared trait makes plant cells
an interesting material with which to study the effects of
hypofractionated radiotherapy, as studying the effects of ion-
izing irradiation on the growth of plant cells could shed more
light on the effects of hypofractionation on rapidly growing
cells.
Much research has been carried out on the effects of low-
dose ionizing radiation on plant growth.5,6 In most cases,
however, the focus of this research is on stimulating growth
and increasing yields. In contrast, very little research has been
done on the use of high dose radiation to slow or halt plant
growth.
Aim: In this study, we  used a plant model to evaluate the
differential effects of fractionated and single high-dose (SHD)
radiotherapy on plant growth.
2.  Materials  and  methods
The study sample consisted of 150 plants from the genus Cap-
sicum annuum (pepper plant) grown in a local greenhouse. All
the plants were grown in exactly the same conditions: same
container type, climate (temperature, light, humidity), and
feeding (soil type, amount of water).
The 150 plants were randomly allocated to one of three
groups (50 plants per group). Plants assigned to group 1 were
considered controls and were not irradiated. Plants in group 2
received 50 Gy of radiation delivered in a fractionated sched-
ule of 10 Gy per dose over 5 consecutive days. Plants allocated
to group 3 received a single, high-dose fraction of 50 Gy. Irra-
diation was delivered via linear accelerator.Fig. 1 – Image of young plants and metric ruler.
Dose simulation was performed with a 30 cm × 30 cm ×
20 cm slab phantom using the ELEKTA PrecisePlan planning
system using a 40 cm × 40 cm ﬁeld to encompass both treat-
ment groups. We  used 6 MV photon beams and the dose was
prescribed to the depth of maximum dose (1.5 cm).
All plants were followed daily for 26 days to assess day-by-
day growth. Growth was measured daily (Figs. 1 and 2) using
a metric ruler.
2.1.  Statistical  analysis
This was a descriptive, randomized study. Plant growth was
measured in cm/day and a simple mean daily growth was cal-
culated with a standard deviation. A level of P ≤ 0.05 was used
to assess signiﬁcance.
3.  Results
The tables show results obtained in each group each day.
Results for the control group (group 1) are shown in Table 1
and Fig. 3, while results for fractionated radiotherapy (group
2) are shown in Table 2 and Fig. 4. Table 3 and Fig. 5 show
the results for the SHD group (group 3). Finally, Fig. 6 shows a
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Fig. 2 – Close-up of plant.
Fig. 3 – Daily changes in mean growth of control plants.
Fig. 4 – Daily changes in mean growth of plants irradiated
on a fractionated schedule.
Table 1 – Daily growth of group 1 (control group).
Day Group 1 (control group)
Mean height
(cm)
Standard
deviation (cm)
Number
(n)
Number of plants with
zero growth
No. of plants dead on
day of measurement
16-07-12 1.29 0.23 47 3 0
17-07-12 1.45 0.18 47 3 0
18-07-12 1.56 0.20 47 3 0
19-07-12 1.92 0.21 47 3 0
20-07-12 1.98 0.22 47 3 0
22-07-12 1.98 0.40 47 3 0
23-07-12 2.03 0.39 47 3 0
24-07-12 2.10 0.36 47 3 0
25-07-12 2.54 0.35 46 3 1
26-07-12 3.06 0.29 46 4 0
28-07-12 3.65 0.37 46 4 0
31-07-12 4.94 0.85 46 4 0
01-08-12 5.73 0.47 46 4 0
02-08-12 5.85 0.57 46 4 0
03-08-12 6.27 0.51 46 4 0
04-08-12 6.89 0.34 46 4 0
05-08-12 6.95 0.36 46 4 0
06-08-12 7.05 0.45 46 4 0
07-08-12 7.24 0.51 46 4 0
08-08-12 7.42 0.59 46 4 0
09-08-12 7.55 0.67 46 4 0
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Table 2 – Growth of plants in group 2 (fractionated radiotherapy
Day Mean height
(cm)
Standard
deviation (cm)
Number (n) of
receiving fraction
16-07-12 1.14 0.26 49 
17-07-12 1.36 0.26 49 
18-07-12 1.57 0.23 49 
19-07-12 1.81 0.24 49 
20-07-12 1.88 0.25 49 
22-07-12 1.90 0.32 48 
23-07-12 1.96 0.34 49 
24-07-12 1.99 0.35 49  
25-07-12 2.19 0.29 49  
26-07-12 2.59 0.34 49 
28-07-12 2.72 0.24 48 
31-07-12 3.43 0.24 48 
01-08-12 3.60 0.24 48 
02-08-12 3.60 0.24 48 
03-08-12 3.53 0.24 48 
04-08-12 3.70 0.24 48 
05-08-12 3.76 0.24 47 
06-08-12 3.93 0.24 47 
07-08-12 4.17 0.24 47 
08-08-12 4.23 0.24 46 
09-08-12 4.32 0.24 46 comparison of the 3 groups in terms of changes in mean
growth. Table 4 shows the mean daily differences in total
growth (in cm)  between groups (Fig. 7).
As Table 4 shows, on day 30, while the control group had
grown to a mean height of 7.55 cm,  the fractionated group
Table 3 – Growth of plants in group 3 (single high dose of 50 Gy
Day Group 3
Mean height
(cm)
Standard
deviation (cm)
Numb
(n)
16-07-12 1.12 0.17 48 
17-07-12 1.33 0.20 48 
18-07-12 1.56 0.18 48 
19-07-12 1.72 0.21 48 
20-07-12 1.82 0.23 48 
22-07-12 1.68 0.24 48 
23-07-12 1.73 0.25 48 
24-07-12 1.78 0.26 48 
25-07-12 1.89 0.22 48 
26-07-12 1.91 0.37 48 
28-07-12 2.07 0.30 48 
31-07-12 2.64 0.43 47 
01-08-12 2.69 0.41 47 
02-08-12 2.68 0.42 47 
03-08-12 2.67 0.41 47 
04-08-12 2.94 0.38 47 
05-08-12 2.95 0.35 47 
06-08-12 2.89 0.37 47 
07-08-12 2.93 0.47 37 
08-08-12 2.96 0.46 35 
09-08-12 2.94 0.45 35 iotherapy 1 8 ( 2 0 1 3 ) 279–285
).
 plants
ated dose
No. of plants
showing zero growth
No. of plants dead on
day of measurement
1 0
1 0
1 0
1 0
1 0
1 0
1 0
1 0
1 0
1 0
1 1
2 0
2 0
2 0
2 0
2 0
2 0
3 0
3 0
3 0
4 0
(group 2) had grown to only 4.32 cm and the hypofractionated).
: single dose of 50 Gy
er No. of plants
showing zero growth
No. of plants dead on
the day of measure
2 0
2 0
2 0
2 0
2 0
2 0
2 0
2 0
2 0
2 0
2 0
2 1
3 0
3 0
3 0
3 0
3 0
3 0
3 10
13 2
15 0
group to only 2.94 cm.  The unirradiated plants used as a con-
trol showed a signiﬁcantly greater growth than both irradiated
groups (P = 0.005). The group that showed the least amount of
growth was the SHD group.
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Table 4 – Mean daily differences in total growth (cm) between groups.
Day Differences in mean plant height between groups
Single high dose of 50 Gy
vs. control group (cm)
Fractionated dose vs.
control group (cm)
Fractionated dose (group 2) vs.
single high dose (group 3) (cm)
16-07-12 0.17 0.15 0.02
17-07-12 0.12 0.09 0.03
18-07-12 0.00 0.01 0.01
19-07-12 0.20 0.11 0.09
20-07-12 0.17 0.10 0.06
22-07-12 0.30 0.08 0.21
23-07-12 0.31 0.08 0.23
24-07-12 0.32 0.11 0.22
25-07-12 0.64 0.35 0.29
26-07-12 1.15 0.47 0.68
28-07-12 1.59 0.93 0.66
31-07-12 2.30 1.51 0.79
01-08-12 3.04 2.13 0.91
02-08-12 3.17 2.25 0.92
03-08-12 3.60 2.74 0.86
04-08-12 3.96 3.19 0.77
05-08-12 4.01 3.20 0.81
06-08-12 4.16 3.12 1.04
07-08-12 4.31 3.08 1.23
08-08-12 4.46 3.18 1.28
09-08-12 4.61 3.24 1.37
Fig. 5 – Daily changes in mean growth of plants irradiated
with a single 50 Gy dose fraction.
F
t
ig. 6 – Comparative chart depicting mean growth in both
reatment groups and the control group.Fig. 7 – Image of all three groups on day 26: control,
high-dose, and fractionated, respectively.
4.  Discussion
Our results clearly illustrate that single high-dose radiothe-
rapy is much more  effective in slowing plant growth than the
fractionated schedule. Such a result, while not unexpected,
supports efforts to further investigate the potential value of
hypofractionated radiotherapy.
Although there are many  differences between plant and
animal cells—particularly the fact that animal cells do not
contain cell walls—the effect of ionizing radiation is similar
in both. Esnault et al., in a review of the effects of ionizing
radiation on genetic material in higher plants, described the
mechanism of action of ionizing radiation on plant DNA.7According to the authors, ionizing radiation causes direct and
indirect damage to DNA through water radiolysis and the
resulting creation of reactive hydroxyl radicals. This process
d rad284  reports of practical oncology an
occurs in a similar manner in all biological systems (animal
and plant), as the initial absorption of ionizing radiation leads
to a cascade of effects that ultimately end in the ﬁnal bio-
logical injury. Because all biological organisms contain water
molecules, water radiolysis is the most important factor in
causing damage to biological organism. As in human tissue,
chromosomal damage is dose-dependent.
An interesting similarity between plant and human cells
is that repeated use of ionizing radiation (either acute or
chronic) triggers radioresistance,8 which may reﬂect an adap-
tive response to radiation.9 This phenomenon suggests that
fractionated schedules may generate radioresistance, and
may explain why plants in our experiment that underwent a
fractionated treatment schedule managed to achieve a greater
mean growth than those in the SHD group. This observa-
tion supports the use of hypofractionation to avoid generating
radioresistance, although the adverse effects of high dose
radiotherapy on healthy cells is an important limiting factor
that must be considered. In addition, it is evident that the
results that we  report here cannot be directly extrapolated to
human tissue cells. However, they do provide further conﬁr-
mation of the differences between conventional and extreme
hypofractionated radiotherapy in cell division.10 As our study
shows, these differences hold true for both plant and human
cells.
Ours is not the only study to evaluate the effects of ion-
izing radiation on plant growth. For example, Kahan et al.11
evaluated the differential effects of small doses of ionizing
radiation on the growth of onion seeds and bulbs. They found
that doses of 6–10 Gy to onion bulblets applied 8–25 days
before planting reduced crop yields by 25% and the number
of large onions by 75%. Similarly, Kovalchuk et al. analysed
the inﬂuence of acute and chronic ionizing radiation on plant
genome stability and global genome expression. They found
that plants exposed to chronic but not acute radiation showed
early ﬂowering. Transcriptome analysis showed fundamental
differences in plant response to acute and chronic exposure
to ionizing radiation.12
Hypofractionation began in the 1960s as physicians sought
to reduce patient discomfort arising from the extended treat-
ment schedules (requiring daily hospital visits) and to save
machine time.13 However, the resulting increase in com-
plications and late sequelae quickly convinced clinicians
to abandon such extreme regimens. It has only been in
the last 10–20 years that hypofractionation has once again
become popular with the advent of more  sophisticated stereo-
tactic, intensity-modulated and image-guided techniques.
Similarly, advances in our understanding of radiobiological
characteristics of different cell types has helped to iden-
tify those tumours that are most amenable (i.e., responsive)
to accelerated fractionation schemes. Emerging clinical evi-
dence is showing that, for several of the most common
cancers needing radiotherapy, the total length of treatment
can be signiﬁcantly shortened without sacriﬁcing efﬁcacy and
tolerability.
In humans, the improved target localization of IMRT, com-
bined with advances in our understanding of radiobiology,
have led to an increased interest in hypofractionated treat-
ment schedules in recent years,14 particularly in prostate and
lung cancer, but also in breast, liver, and kidney cancers.iotherapy 1 8 ( 2 0 1 3 ) 279–285
In a recent study, Arcangeli et al. found that, at a median
follow-up of 32 months, prostate cancer patients who  received
hypofractionated treatment had signiﬁcantly less biochem-
ical failure rates than patients who received conventional
fractionation. Moreover, no signiﬁcant differences in Grade
2 gastrointestinal (GI) or genitourinary (GU) toxicity were
observed. The authors conclude that these ﬁndings support
the role of hypofractionation in increasing tumour control
without increasing toxicity.15 Zelefsky et al. recently reported
outcomes of treatment with a high single-dose image-guided
IMRT for metastatic renal cell cancer, with very good results.16
Similarly, SBRT is now the standard of care for inoperable
lung tumours.17 However, despite the good results achieved
with IMRT, SBRT, and other new technologies, toxicity con-
tinues to be an important concern due to the high doses
used.18
Another issue surrounding hypofractionation is related to
difﬁculties identifying the optimal fractionation schedule. As
in the study by Arcangeli and colleagues, most phase 1 and
phase 2 studies of prostate cancer treated with hypofrac-
tionated IMRT  have reported acceptable levels of late GI and
GU toxicity. However, in many  of these studies follow up is
too short.19 The same applies to studies of hypofractionated
radiotherapy in breast cancer, in which published randomized
controlled studies have shown the effectiveness and safety
of modest hypofractionation. However, once again the rela-
tively short follow-up (5–10 years) precludes any deﬁnitive
conclusions.20 That said, the use of hypofractionated schemes
in breast cancer, particularly accelerated partial breast irradi-
ation (APBI) continues to increase. Several large randomized
studies are currently in progress, with encouraging early
results.21
5.  Conclusion
The potential clinical beneﬁts of a short course of radiotherapy
are myriad, not only in terms of local and distant control and
survival, but in other ways as well. For example, fewer frac-
tions would ease the burden on the patient by reducing the
number of treatment sessions vs. conventional fractionation.
In addition to these time savings, hypofractionation can also
reduce costs.
The study presented here adds incremental knowledge to
our understanding of the powerful effects of hypofractiona-
tion. As our ﬁndings conﬁrm, extreme hypofractionation is
much more  effective than conventional fractionation in slow-
ing and halting cell growth. This suggests a need to continue
investigating the use of hypofractionation schemes to achieve
better results. However, the use of such schemes will require
furtherer improvements in the accuracy of radiotherapy deliv-
ery so that surrounding healthy tissues are protected while
greater amounts of radiation are delivered.
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